Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Fortress Bio’s Portfolio Of Marketed Drugs Could Soon See Three Additions

Fortress Biotech, Inc.

Fortress Biotech Inc. (NASDAQ: FBIO) is a biopharmaceutical company focused on developing a range of high-potential treatments on its own and through its growing portfolio of subsidiaries and partner companies. With nine products already on the market and more than 30 programs in development, the biopharmaceutical company helps deliver innovative drug therapies to patients who have a wide range of diseases and disorders. Here are three of the most significant breakthrough developments it achieved this year. Checkpoint’s Cancer Immunotherapy Aims To Add Second Treatment Indication Checkpoint Therapeutics Inc. (NASDAQ: CKPT) announced positive interim results in June from a registration-enabling clinical trial of its anti-PD-L1 checkpoint inhibitor. The novel cancer immunotherapy is being studied as a possible treatment for advanced cutaneous squamous cell carcinoma (cSCC), a difficult-to-treat skin cancer. The current first-line treatment for cSCC is surgery to remove the tumor or radiation therapy to destroy the tumor. However, some patients aren’t candidates for surgery or radiation, either because of poor health or because cancer has spread or become too advanced. Cosibelimab is an immunotherapy drug that works by blocking the PD-L1 inhibitor, an immune checkpoint inhibitor on the surface of cells that tells the body’s immune system not to attack that particular cell. Cancer uses those same checkpoint inhibitors to trick the immune system into believing the cancerous cell is a normal healthy cell that it should not attack. By blocking PD-L1, cosibelimab can remove cancer’s ability to escape detection and allow the patient’s own immune system to better identify and attack cancerous cells. In the registration-enabling clinical trial, cosibelimab achieved a response rate of 54.8% — far exceeding the minimum 25% target. Checkpoint plans to discuss the potential of adding locally advanced cSCC as a second indication in addition to metastatic cSCC with the Food and Drug Administration (FDA) as it prepares its biologics license application for submission around year-end. Checkpoint provides a 4.5% royalty on net sales and a 2.5% annual equity dividend to Fortress Bio in exchange for its operational, strategic, administrative, financial, and legal support. A First-Of-Its-Kind Menkes Disease Treatment Edges Closer To FDA Approval Last year, Cyprium Therapeutics Inc., a Fortress Bio partner company, announced the initiation of rolling submission of its new drug application (NDA) with the FDA for its novel treatment for Menkes disease. The company presented additional data in March at the 2022 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. Cyprium continues to progress toward the completion of its NDA submission. Menkes disease is a rare but fatal genetic condition that impairs the ability to transport copper through the body. This results in abnormally low levels of copper in the brain and liver along with abnormally high levels in the kidney and intestines. Symptoms include poor muscle development, low weight, and cognitive difficulties. The difficult-to-diagnose progressive disease has no approved treatments, and most children with Menkes disease will die within the first three years of life. CUTX-101 is a copper histidinate (CuHis) injection that can be administered directly into the body to restore copper levels. Because Menkes disease affects the body’s ability to absorb copper through the gastrointestinal tract, direct injections are meant to bypass the GI tract and deliver copper straight to the bloodstream. Clinical data showed that CUTX-101 improved neurodevelopmental outcomes and survival in treated patients, including a nearly 80% reduction in the risk of death. If approved, CUTX-101 has the potential to be the first FDA-approved treatment for Menkes disease. As with Checkpoint, Fortress Bio receives a 4.5% royalty and 2.5% annual equity dividend from Cyprium. A More Potent Oral Rosacea Antibiotic May Offer Lower Risk Of Treatment Resistance Journey Medical Corp. (NASDAQ: DERM) is a dermatology biopharmaceutical company founded by Fortress Bio. Journey announced 50% enrollment in its Phase 3 clinical trial of a novel rosacea treatment in August. DFD-29, the drug candidate being studied in the clinical trial, is a minocycline-based compound meant to treat rosacea using its anti-inflammatory and antimicrobial properties. Minocycline is already used to treat other inflammatory conditions ranging from acne to rheumatoid arthritis because it can block pro-inflammatory cytokines and other inflammatory processes that cause flare-ups. It’s typically administered as a topical treatment, which can help with milder symptoms but doesn’t provide enough relief for severe cases. Doctors typically prescribe a course of doxycycline for rosacea patients with severe flare-ups. But the clinical data on DFD-29 showed that it was almost twice as effective as doxycycline at reducing lesions and overall symptom improvement. DFD-29’s modified release capsule is also meant to counter the bacterial resistance that often develops with frequent antibiotic use. Rather than immediate release, the capsule slowly releases small doses of minocycline over time. The subantimicrobial dose is meant to be low enough to avoid triggering selection pressure for bacterial resistance while still offering the anti-inflammatory benefits of the treatment. Topline data from this latest Phase 3 clinical trial is expected in the first half of 2023, and the company expects to file a new drug application by the end of that year. Fortress Bio currently owns a controlling stake in Journey Medical. Fortress Biotech, Inc. ("Fortress") is an innovative biopharmaceutical company focused on acquiring, developing and commercializing high-potential marketed and development-stage drugs and drug candidates. The company has nine marketed prescription pharmaceutical products and over 30 programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company's portfolio of product opportunities. Fortress has established partnerships with some of the world's leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca plc, City of Hope, Fred Hutchinson Cancer Research Center, St. Jude Children's Research Hospital, Nationwide Children's Hospital and Sentynl Therapeutics, Inc. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Jaclyn Jaffe and Bill Begien +1 781-652-4500 ir@fortressbiotech.com Company Website https://www.fortressbiotech.com/

October 06, 2022 08:00 AM Eastern Daylight Time

Understanding the Importance of Lowering Your Cholesterol to Help Decrease Your Risk for Heart Disease

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/_EQumoCuW6U High cholesterol is the single biggest cause of illness and death in America affecting more than 94 million adults in the United States, according to the Centers for Disease Control and Prevention. For some people, it is their genes that lead to very high LDL (“bad”) cholesterol. One of the most common causes of genetically high cholesterol is familial hypercholesterolemia (FH). FH impacts 1 in 250 individuals worldwide, and if untreated it leads to early heart attacks and strokes. There are already decades of research showing that high LDL cholesterol is a major risk factor for heart disease. And recent data has shown that having lower LDL for longer is one of the best things people can do to reduce your risk for heart disease. While a healthy diet and exercise are important for many reasons, diet and exercise alone cannot lower many people’s cholesterol to a safe level, especially if they have a genetic cholesterol-related disorder. There are medications that can significantly reduce the level of cholesterol in the bloodstream. Statins are the first line of defense when it comes to getting your LDL-cholesterol to a safer level. A new study on the safety and effectiveness of statins shows the vast majority of people do not have side effects from statins, and they not only reduce the LDL cholesterol, they also reduce the risk for heart attacks and cardiac death. The American College of Cardiology also just updated its expert guidance for medical experts treating patients and suggested an LDL target of less than 55 mg/dL for individuals with established cardiovascular disease. The Family Heart Foundation has a variety of resources for understanding treatment options for lowering high cholesterol and treating FH. Visit MoreFamiliesMoreHearts.org to learn more. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

October 04, 2022 03:00 PM Eastern Daylight Time

Video

US Digestive Health Expands Presence into Delaware Through Partnership with Delaware Center for Digestive Care

US Digestive Health

US Digestive Health (USDH), a network of top-rated gastrointestinal (GI) practices managed by US Digestive Health Management (USDHM), a management services organization created to expand access to high-quality, cost-effective gastroenterology care, announced today that it has partnered with Delaware Center for Digestive Care (DCDC), a specialty practice based in Newark, Delaware. The partnership with DCDC will bring an additional three locations, two ambulatory surgery centers, over 35 providers, and more than 140 employees to the US Digestive Health Management network, further positioning USDH as the leading GI practice in the Northeast. With the addition of this new partnership, US Digestive Health Management now oversees a network of over 200 gastroenterology professionals and service providers, along with 29 locations, 17 ambulatory surgery centers, and over 950 employees. US Digestive Health Management works hand-in-hand with gastroenterology partner practices throughout Central and Southeastern Pennsylvania, Western Pennsylvania, and now Delaware, to meet the challenges inherent in the fast-changing healthcare landscape. USDHM provides innovative business management and technology solutions that ease administrative burdens and allow physicians to focus on clinical care. “USDH brings the type of high-quality care, elevated standard of medicine, innovation in diagnosis, and treatment our patients deserve,” added Dr. Mark Corso, DCDC Physician Board Member. “Through this partnership with USDH, our team of board-certified GI doctors and specialists can focus on patient care,” said Dr. Jared Hossack, DCDC Physician Board Member. “DCDC has established a strong reputation in the Delaware market as a preferred gastroenterology provider, and the practice has proven its commitment to patients by offering innovative options in the GI field while prioritizing patient-centric care. USDH is proud to join with DCDC and to serve the people of Delaware,” said Jerry Tillinger, CEO of US Digestive Health Management. USDH was formed in 2019 by Amulet Capital Partners, LP (“Amulet”), a middle-market private equity investment firm based in Greenwich, CT, focused exclusively on the healthcare sector, in partnership with member practice partner physicians. “We are excited to see USDHM expand to the Delaware region and add yet another industry-leading GI practice to its partnership network,” said Gabriel Luft, Partner at Amulet. “DCDC exhibits the type of patient experience and innovative approach that USDH looks to provide for patients across both Pennsylvania and Delaware.” Provident Healthcare Partners (“Provident”), a leading healthcare investment banking firm, advised DCDC on the partnership. For more information, please visit https://usdigestivehealth.com/. About US Digestive Health US Digestive Health (USDH) is the leading gastroenterology practice in the Northeast. USDH was formed in 2019 by Amulet Capital Partners, LP ("Amulet"), a healthcare private equity investment firm based in Greenwich, Connecticut, in partnership with member practice partner physicians. USDH aims to deliver high-value, patient-centric digestive healthcare by bringing new insight into the care, treatment, and prevention of digestive health disorders. USDH consists of 29 locations, 17 ambulatory surgery centers, over 200 GI providers, and more than 950 employees throughout Southeastern, Central, and Southwestern Pennsylvania, and Delaware. About Amulet Capital Partners, LP Amulet Capital Partners, LP is a middle-market private equity investment firm based in Greenwich, CT, focused exclusively on the healthcare sector. Amulet seeks to achieve long-term capital appreciation through privately negotiated investments in companies. Amulet Capital Partners focuses on those segments it believes have the most attractive long-term fundamentals with a target investment size generally between $25 million to $150 million. For additional information, please visit www.amuletcapital.com. Contact Details US Digestive Health Lauren Stralo +1 484-747-9692 lstralo@levlane.com Amulet Capital Partners, LP Jon Keehner / Erik Carlson +1 212-355-4449 Company Website https://usdigestivehealth.com

October 04, 2022 10:00 AM Eastern Daylight Time

Industrial Defender Appoints Gabe Authier as Chief Product Officer

Industrial Defender

Industrial Defender, a leader in operational technology (OT) cybersecurity solutions, today announced the appointment of Gabe Authier as CPO. This addition strengthens the company’s bench of technical executives and positions it for success in 2023 and beyond. Authier has held product management roles at both Tripwire and Belden, and his comprehensive knowledge of the industrial cybersecurity space and cloud-native solutions will further enrich Industrial Defender’s product development roadmap. “Industrial Defender continues to add incredible new talent to the team. Gabe’s experience architecting customer-centric product roadmaps, building cloud-native technologies and creating innovative solutions for the industrial space aligns well with our organizational goals,” said Jay Williams, CEO of Industrial Defender. “I am confident he will be an essential contributor to our continued success as a global leader in OT cybersecurity solutions.” “We see a massive opportunity right now to help critical infrastructure companies mature their cybersecurity programs beyond basic visibility solutions. Identifying, monitoring and managing asset data from a single tool is the next generation of OT security,” said Authier. “I couldn’t be more excited about the opportunity to shape Industrial Defender into the go-to OT data platform for the future.” Authier brings over 20 years of experience in product management and information technology and is passionate about customer-centric software development. He holds a BS in Systems Engineering from University of Arizona and an Executive MBA from the University of Oregon. About Industrial Defender Industrial Defender protects the world’s critical infrastructure from cyberattacks. As a leader in OT cybersecurity innovation, the company’s scalable platform is used by organizations around the world to empower security stakeholders with actionable data from their OT and IIoT infrastructure, enabling them to make informed risk management decisions and manage their OT cybersecurity program in a concise, single vendor dashboard. Learn more at www.industrialdefender.com. Contact Details Industrial Defender Erin Anderson +1 617-675-4206 eanderson@industrialdefender.com Company Website https://www.industrialdefender.com

October 04, 2022 09:09 AM Eastern Daylight Time

Development of New Drugs to Target Lyme and Other Infectious Diseases Subject of a New Webinar Now Available From Quidel Corporation

Quidel Corporation

Lyme disease is the fastest-growing vector-borne disease in the United States, and its increased prevalence is challenging the scientific community to look for new ways to diagnose and treat this worrisome infection. One answer is found in the discovery of novel drugs; and the breakthrough efforts taking place in this arena are the subject of a new webinar made available by Quidel Corporation, the California-based diagnostic health care manufacturer known for successfully developing rapid diagnostic health solutions. The 90-minute webinar, available free at https://education.quidel.com/category/lyme-disease, will explain what a small molecule drug is and how it works, identify the methods used to unearth a new drug by high-throughput screening, and discuss how to recognize the complexities involved in developing a new drug for infectious disease in general. It will also provide an overview as to the current antibiotics used for treating Lyme disease and explore how powerful new drugs—novel inhibitors—can selectively target Borrelia burgdorferi (the bacterium that causes Lyme disease). The webinar is PACE-accredited and sponsored in collaboration with Global Lyme Alliance. Conducting the webinar is Timothy Haystead, Ph.D., professor of pharmacology and cancer biology at Duke University School of Medicine. Dr. Haystead’s current research is focused on the use of chemical biology approaches to define novel drug targets. These drug targets are focused on the treatment of hypertension, obesity, cancer, inflammatory and infectious disease. Dr. Haystead received his Ph.D. from the University of Dundee, Scotland; and he completed post-doctoral work in pharmacology at the Howard Hughes Medical Institute, University of Washington, Seattle. The new webinar is the latest in an ongoing series sponsored by Quidel that has featured noted scientists, researchers and physicians discussing issues surrounding the prevalence of Lyme disease in America, including ways to reduce the chances of infection, early detection and treatment options. The timing and relevance for these webinars is particularly important as Lyme disease is on the rise to record numbers with approximately 476,000 new cases annually in the United States alone. Quidel is the diagnostic health care manufacturer behind the industry’s most rapid and reliable in-office test for Lyme disease, Sofia ® 2 Lyme FIA. It is the only FDA-cleared rapid point-of-care test on the market, which provides the patient and physician with indicative results in as few as three minutes, as opposed to days, which has historically been the norm (and during which time organisms can spread and become systemic). It can be performed in the privacy of a doctor’s office or local clinic; and it is the only test that can get results from a simple finger prick of blood. About Quidel Corporation Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names, Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’ s comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. With products made in America, Quidel’ s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world. For more information about Quidel, visit quidel.com. Contact Details Jim Yeager +1 818-264-6812 jim@breakwhitelight.com Company Website http://Quidel.com

October 04, 2022 06:00 AM Pacific Daylight Time

Is This The Filling To Fix America’s Dental Insurance Toothache?

DentalPlans.com

Healthcare costs remain a crisis for ordinary Americans. Most health insurance is still employer-provided — it represents over half of all coverage — but many households are feeling the squeeze under hiked premiums, with over 23 million people forking out large contributions relative to their income, whether on increased deductibles or out-of-pocket expenses. Struggling under these exorbitant industry costs, over 27 million Americans are still uninsured. This number has barely changed since 2016, despite the COVID-19 pandemic, and represents the care provision crisis in the healthcare industry. Currently a staggering one-third of working-age American adults — over 70 million people — do not use dental care, with most saying they simply cannot afford it. Looking to make dental care more accessible is DentalPlans.com, a marketplace for dental savings plans leading the industry to bring affordable dental solutions to over a million users since 1999. Better Offerings Than The Tooth Fairy? Of the one-third of Americans who currently do not have dental coverage, almost 60% say it is because of exorbitant costs, while over 20% report that dental care is an out-of-pocket expense not covered by their employer, according to data compiled by DentalPlans.com. DentalPlans.com is looking to change this by pairing people with dental savings plans that get them the treatment they need at a price they can afford. As an online marketplace for affordable dental savings plans, DentalPlans.com is a one-stop-shop connecting patients with over 30 plans and over 140,000 participating dentists. Dental savings plans are not insurance but are similar to a membership at a club, where a yearly subscription provides members with access to discounted rates. Plans offer several perks. They cost an average of between $79.95 and $199.95 and allow customers to access a wide range of services at the majority of dental practices. Customer surveys indicated an average of 50% savings when they switched to a dental savings plan through DentalPlans.com, though savings may vary by provider, location, and membership type. Dental savings plans are a straightforward option, offering flat discounted rates ranging from 10% to 60%, without having health restrictions or monthly payments. They also give the user the flexibility to attend the dentist as frequently as necessary without exclusions or limitations, and plans often include savings for cosmetic and orthodontic procedures, specialties that may not be covered by an employer’s dental insurance. Dental savings plans also offer quick activation to get patients’ plans with no health restrictions or annual limits on the savings available. DentalPlans.com prides itself as a leader in the dental savings plans industry. Its collection of over 30 plans makes it the largest marketplace, with the plans offered through its platform accepted by 7 in 10 practicing dentists nationwide. It features low-hassle signups and provides flexibility when it comes to changing plans, recognizing that dental needs can change quickly as a result of a broken tooth or the sudden necessity of a root canal. The range of choices and convenience at DentaPlans.com offers a path forward for those who are seeking quality dental care but are unsure of their options. To learn more about DentalPlans.com, visit its website. Customer surveys indicate average savings of 50%. Savings may vary by provider, location, and membership type. DentalPlans.com, founded in 1999, is a leading online marketplace for dental savings plans in the U.S., helping more than a million people to affordably access quality healthcare services. Our mission is to empower consumers with the tools, information, and services that they need to live happier, healthier lives. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Matthew Wong matthew.wong@wpromote.com Company Website https://www.dentalplans.com/

October 04, 2022 08:00 AM Eastern Daylight Time

United Network for Organ Sharing Names New Interim CEO

United Network for Organ Sharing

Maureen McBride, Ph.D. assumed the role of interim CEO of United Network for Organ Sharing (UNOS) on Saturday, October 1. UNOS is the mission-driven non-profit serving as the engine powering the nation’s organ donation and transplant system, under contract with the federal government. McBride is the first woman and the first person with a Ph.D. to hold this position. Prior to this role, McBride served for 27 years in a variety of senior leadership roles at UNOS, most recently as the Chief Operating Officer. McBride has already re-shaped her senior leadership team, naming patient engagement as a high priority. “As the nation’s organ donation and transplant system reaches a crucial turning point, I am incredibly honored to undertake this important role,” McBride said. “Our community has seen lifesaving success over the previous decades and together, we just surpassed the historic milestone of 1 million transplants thanks to so many generous donors and their families. From increasing transplants to expanding equity, we are proud of everything our community has accomplished, but we also believe that we can and must do more.” In her new position, McBride is committed to working with the UNOS Board, federal partners, Congress, and members of the donation and transplant system to pursue projects and initiatives that build on ongoing successes while addressing community needs and concerns. “I and my team share a bold vision for a more equitable, inclusive, and responsive UNOS,” McBride continued. “The field is constantly evolving and we are evolving with it. Our community is both innovative and forward-looking, and working together, we will challenge ourselves to reach even higher heights.” Key areas of focus identified by McBride for system-wide advancement include patient engagement and empowerment, advocating for holistic, evidence-based, patient-centered policy solutions at the federal level, and optimizing the requirements of the OPTN Contract, including opportunities to better support research into equitable access to care and the national waitlist. McBride will seek support from both the Board of Directors and the community for these and other improvement opportunities. The Congressionally-mandated report from the National Academies of Sciences, Engineering and Math (NASEM), as well as the report from the Senate Committee on Finance, will continue to inform efforts to improve, expand and engage. “Dr. McBride has the know-how, the experience, the relationships and the integrity to lead UNOS into an even brighter future,” said Jerry McCauley, M.D., President of the UNOS Board of Directors. “From her robust working relationship with the Health Resources and Services Administration (HRSA) to her decades of experience managing, leading and serving at UNOS, Dr. McBride is uniquely qualified to serve as interim CEO and to help lead the community during this unprecedented moment.” The Board of Directors has begun a national search for a permanent UNOS CEO. About UNOS United Network for Organ Sharing (UNOS) is the mission-driven non-profit serving as the nation’s transplant system under contract with the federal government. We lead the network of transplant hospitals, organ procurement organizations, and thousands of volunteers who are dedicated to honoring the gifts of life entrusted to us and to making lifesaving transplants possible for patients in need. Working together, we leverage data and advances in science and technology to continuously strengthen the system, increase the number of organs recovered and the number of transplants performed, and ensure patients across the nation have equitable access to transplant. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

October 03, 2022 10:17 AM Eastern Daylight Time

Image

Ready for Ron Announces Military & Veterans Initiative

Ready for Ron

Ready for Ron, the only credible independent group working to Draft Florida Governor Ron DeSantis to run for President, announced a new initiative to recruit military, veterans, and families to sign its petition to encourage Ron DeSantis to run in 2024. ‘Veterans Ready for Ron’ led by Captain Bob “Shoebob” Carey, US Navy (Ret), will actively engage veterans, military and family voters, and veterans organization leaders. Carey had previously led the RNC’s highly successful 2016 Veterans programs, and numerous veterans and military engagement campaigns. Governor DeSantis is a U.S. Navy veteran, deploying to Iraq in support of the Navy’s SEALs, receiving a Bronze Star Medal, and as Governor is the Commander in Chief of the 12,000 members of the Florida National Guard. “Supporting Ron DeSantis is an easy decision for those who wore the uniform for our country,” stated Captain Bob “Shoebob” Carey, leader of the Veterans Ready for Ron effort. “His record supporting veterans and those in military service is unmatched.” “America needs Governor Ron DeSantis to run for President in 2024, to rebuild and restore our military and honor the pledges this country made to those military veterans once they leave service. He is a decorated veteran, runs one of the largest National Guard forces in the country, and tries to make up for VA ineptitude by building additional veteran assistance programs within his state of Florida,” Carey continued. As a Member of Congress, then Representative DeSantis was a leader on veterans issues, getting bills passed into law that restored combat wounded veterans’ unjustly reduced severance benefits, made Stolen Valor acts a crime, getting a Washington, DC memorial for veterans of the Global War on Terror, getting the VA to pay for service dogs for disabled veterans, and awarding the Congressional Gold Medal to American Ace fighter pilots. Veterans Ready for Ron is recruiting and deploying prominent veterans to lead a public effort to raise awareness, recruit additional veteran and military family voters, and build the veteran organization leadership support for a DeSantis candidacy. “I am thrilled to be working with Bob on this important initiative,” stated Ready for Ron Chief Political Strategist Ed Rollins. “His record of engaging with patriotic Americans who selflessly served our country is impressive. We are glad he is on the Ready for Ron team and look forward to building a movement together.” Bob Carey was a driving force behind the most successful military and veteran voter engagement campaigns in modern American political history. For the 2014 and 2016 campaigns, Bob Carey was National Director of Military and Veteran Engagement for the Republican National Committee, recruiting 50 full-time veteran staffers nationwide, more than 400 active veteran volunteer leaders, more than 500 members of state and regional military and veteran “Task Forces” to support the Republican National Committee and the Trump election effort, while also identifying 1.8 million voters nationwide in various databases as military and veteran voters. Republicans won the veteran vote by 27 percentage points in 2016, the greatest margin of victory ever. “I’m asking all military and veterans to join me in convincing Governor Ron DeSantis, U.S. Navy combat veteran, to bring to the rest of the country his leadership and understanding of what the military and veterans need from their Commander in Chief,” Carey continued. The declining economy, inflation, crime, and erosion of the American military significantly impact veterans and military families. We need confident, dependable, and proven leadership like only Ron DeSantis can deliver to turn the tide.” Since its launch in late May, Ready for Ron has enlisted tens of thousands of supporters, generated significant media attention, and run hundreds of ads to convince Ron DeSantis to run for President. Ready for Ron has emerged as the only credible independent organization in support of a Ron DeSantis candidacy. Americans are encouraged to sign the petition at readyforron.com to draft Ron DeSantis to run in 2024. ### For more information or to schedule an interview with a Ready for Ron or Vets Ready for Ron spokesperson, contact Dan Rene at 202-329-8357 or dan@readyforron.com. Contact Details Dan Rene +1 202-329-8357 dan@readyforron.com Company Website https://www.readyforron.com/

October 03, 2022 10:00 AM Eastern Daylight Time

EF Hutton Reiterates Buy Rating On HCTI, Second Time in 2022

Healthcare Triangle, Inc.

On September 28, 2022, Healthcare Triangle Inc (NASDAQ: HCTI) received a Buy rating with a price target of $2.00 in an analyst report by EF Hutton. EF Hutton analyst Constantine Davides, CFA, said “We are reiterating our Buy rating on HCTI. We continue to like the risk-reward of shares here, as HCTI continues to scale its proprietary Platform offerings while expanding its Managed Services business.” This is the second Buy rating report released by EF Hutton on HCTI in 2022. On March 14, 2022, Davides initiated coverage with a Buy rating on Healthcare Triangle and a price target of $4.00. Here are the key points from the report: Platform Services We view the continued adoption of HCTI's Platform offerings as a key component of potential share appreciation (multiple expansion) and an improved financial profile (predictable/recurring revenue mix and long-term margin expansion). We believe that HCTI has approximately six Platform customers, up from four at the end of 1Q, and we would expect that total to expand steadily across the next several quarters. We are projecting $4.7 million in Platform revenue in 2022 (10% of revenue), growing to $8 million by 2024 (13% of revenue). Managed Services Along with the focus on Platform, we continue to expect HCTI to focus on the growth of this recurring revenue stream. We note that YTD Managed Services revenue growth has been negatively impacted by a change in the way HCTI reports partner pass-through revenue, which has had an optically negative impact on 2022 GAAP revenue with no impact on gross profit. Cash and cash flow A recent (July 2022) equity financing provided HCTI with $5.8M in net proceeds. Although HCTI has been opportunistically repurchasing its own shares, we would prefer that management allow cash to build on its balance sheet rather than deploy capital more aggressively toward repurchases, given the challenging macro backdrop. Free cash flow (FCF) was positive in 1Q and 2Q and we expect FCF generation to remain sound across the next several quarters. Updating target and initiating 2024 estimates Our target moves to $2.00 from $4.00 (2.3x 2023 revenue) given recent multiple compression in the space (our target multiple goes to 1.5x 2023 revenue) and other model adjustments (projected cash and share count). We are initiating our 2024 revenue estimate of $61.3M (+10%). HCTI recently traded at 0.3x our 2023 revenue estimate. Risks HCTI is capital-constrained and has above-average customer concentration risk; its largest customer generated 39% of 2Q revenue. The company’s CEO and CFO also serve as officers of another publicly traded company, SecureKloud Technologies, Inc., which owns 65% of HCTI’s common equity. HCTI has a relatively small float and is thinly traded. View the original report by EF Hutton here. Analyst Certification I, Constantine Davides, CFA, certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) and subject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report. Company-Specific Disclosures EF Hutton, division of Benchmark Investments, LLC managed or co-managed a public offering of securities for Healthcare Triangle, Inc during the past 12 months. EF Hutton, division of Benchmark Investments, LLC or its affiliates received compensation from Healthcare Triangle, Inc for investment banking services within the past twelve months, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report General Disclosure This report has been produced by EF Hutton, division of Benchmark Investments, LLC and is for informational purposes only. It does not constitute solicitation of the sale or purchase of securities or other investments. The information contained herein is derived from sources that are believed to be reliable. Prices, numbers, and similar data contained herein include past results, estimates, and forecasts, all of which may differ from actual data. These prices, numbers, and similar data may also change without prior notification. This research report does not guarantee future performance, and the information contained herein should be used solely at the discretion and responsibility of the client. Neither EF Hutton nor its affiliates accept any liability or responsibility for any results in connection with the use of such information. This research report does not consider specific financial situations, needs, or investment objectives of any client, and it is not intended to provide tax, legal, or investment advice. Clients are responsible for making final investment decisions and should do so after a careful examination of all documentation delivered prior to execution, explanatory documents pertaining to listed securities, etc., prospectuses, and other relevant documents. EF Hutton and its affiliates may make investment decisions based on this research report. In addition, EF Hutton and its affiliates, as well as employees, may trade in the securities mentioned in this research report, their derivatives, or other securities issued by the same issuing companies in this research report. This research report is distributed by EF Hutton and/or its affiliates. The information contained herein is for client use only.EF Hutton holds the copyright on this research report. Any unauthorized use or transmission of any part of this research report for any reason, whether by digital, mechanical, or any other means, is prohibited. If you have any questions, please contact your sales representative. Additional information is available upon request.Certain company names, product and/or service names that appear in this research report are trademarks or registered trademarks of EF Hutton or other companies mentioned in the report. Copyright 2022 EF HUTTON, division of Benchmark Investments, LLC. Contact Details Healthcare Triangle, Inc. Michael Campana michael.c@healthcaretriangle.com Company Website https://www.healthcaretriangle.com

October 03, 2022 09:28 AM Eastern Daylight Time

1 ... 201 202 203 204 205 ... 305